July 2018
Volume 59, Issue 9
Free
ARVO Annual Meeting Abstract  |   July 2018
Efficacy of adjuvant topical dorzolamide-timolol in patients with neovascular age-related macular degeneration unresponsive to anti-vascular endothelial growth factor therapy
Author Affiliations & Notes
  • Joo Yeon Kim
    National Health Insurance Service Ilsan Hospital, Seoul, Korea (the Republic of)
    Ophthalmology, Yonsei university college of medicine, Seoul, Korea (the Republic of)
  • Jihwan Lee
    Ophthalmology, Yonsei university college of medicine, Seoul, Korea (the Republic of)
  • Sung Chul Lee
    Ophthalmology, Yonsei university college of medicine, Seoul, Korea (the Republic of)
  • Christopher Seungkyu Lee
    Ophthalmology, Yonsei university college of medicine, Seoul, Korea (the Republic of)
  • Footnotes
    Commercial Relationships   Joo Yeon Kim, None; Jihwan Lee, None; Sung Chul Lee, None; Christopher Seungkyu Lee, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 2389. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Joo Yeon Kim, Jihwan Lee, Sung Chul Lee, Christopher Seungkyu Lee; Efficacy of adjuvant topical dorzolamide-timolol in patients with neovascular age-related macular degeneration unresponsive to anti-vascular endothelial growth factor therapy. Invest. Ophthalmol. Vis. Sci. 2018;59(9):2389. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate the efficacy of adjuvant topical dorzolamide-timolol in neovascular age-related macular degeneration (AMD) patients unresponsive to anti-vascular endothelial growth factor (VEGF).

Methods : This retrospective, interventional study included 15 neovascular AMD patients unresponsive to anti-VEGF. Patients were instructed to use topical dorzolamide-timolol twice daily in the eye with neovascular AMD, and an anti-VEGF therapy was performed at each visit with the same fixed interval and the same agent as before the addition of dorzolamide-timolol. Central macular thickness, the maximal subretinal fluid height, and the maximal pigment epithelial detachment height were measured at baseline and every visit.

Results : The mean central macular thickness decreased from 383.47μm at baseline to 298.27μm at final visit (p=0.041). The mean maximal subretinal fluid height decreased from 105.00μm at baseline to 58.27μm at final visit (p=0.021). Complete resolution of subretinal fluid was observed in 3 of 11 eyes with subretinal fluid type. There was no significant change in the maximal pigment epithelial detachment height and visual acuity. The mean intraocular pressure decreased significantly from 14.87mmHg at baseline to 12.33mmHg at final visit (p=0.005).

Conclusions : An adjuvant use of topical dorzolamide-timolol was effective in neovascular AMD patients with persistent exudation despite anti-VEGF therapy with fixed intervals.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×